SEC Form 4 · accession 0001562180-18-000318
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Haddock
Officer — CFO
Period of report
Jan 16, 2018
Accepted (ET)
Jan 16, 2018 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 16, 2018 | M | 14,025 | $3.77 | A | 36,368 | D | |
| Common Stock | Jan 16, 2018 | S | 7,500 | $13.73 | D | 28,868 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $3.77 | Jan 16, 2018 | M | 14,025 | D | Jul 28, 2017 | Jul 28, 2026 | Common Stock | 14,025 | 540,975 | D |
Explanation of responses
- F1These trades were made pursuant to a Rule 10b5-1 trading plan.